English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Carnitine and coenzyme Q10 are important for myocardial- mitochondrial function, and are defi- cient in patients with congestive heart failure. It is possible that supplementation with ubiquinol + l- carnitine may be pro- tective among these patients, which may improve the quality of life and morbidity in heart failure. Subjects and Methods: In this controlled trial, the effects of carni Q-gel (L-carnitine fumarate 2250mg/day+hydrosoluble reduced ubiquinol 270mg/day) were examined for 15 months, in 31 (intervention group A) and another 31(control group B) patients with heart failure. Hospitalization due to worsening of heart failure, heart transplantation, and deaths were the combined endpoints. Results: Echo cardiographic ejection fraction was lower at baseline (38.8±7.6 v/s 39.3±6.7%) among both the group of pa- tients, indicating class II- IV heart failure. Baseline serum CoQ10 (0.21±0.11 v/s 0.19+0.10ug/ml) was low, however, after 12 weeks, serum CoQ showed a signifi- cant increase in the carniqgel group compared to the control group (2.7±1.2 v/s 0.76±0.14 ug/ml). After treatment for 12 months, the quality of life visual analogous scale revealed that dyspnea, palpitation and fatigue and NYHA class II-III-IV, which were present at rest, in all the patients, at baseline, showed beneficial effects in the intervention group compared to the placebo group. Six minutes walk test showed that there was a significant greater benefit in walking in the intervention group (215±17.6 v/s 281±20.6, P<0.02) compared to the placebo group (218.4±17.6 v/s 245.7±17.1, P<0.05). A change in the symptom scale showed that majority of the patients had improvement in the intervention group compared to the con- trol group respectively (28 v/s 12 patients, P<0.02). The deaths (3 vs 8) and hospitalizations due to worsening of heart failure (2 vs 11) among intervention and control group respectively, were significantly lower in the carniqgel group com- pared to the control group (5 vs 19, P<0.02). Five patients had nausea and vomiting, which were controlled with sympto- matic treatment. Treatment with carniqgel was stopped after 12 months. Follow up after another 3 months (total 15 months) revealed that there was a worsening of NYHA class heart failure, as well as in the quality of life symptom scale and physical performance, assessed by 6-min walk test. There was a nonsignificant increase in hospitalizations in the in- tervention group after cessation of carniqgel softsules, compared to hospitalizations during the last 3 months. Conclusions: The findings indicate that treatment with ubiquinol +L-carnitine fumarate can cause a significant improve- ment in the quality of life, exercise capacity, as well as NYHA heart failure, which became worst after cessation of CoQ. There was a significant greater benefit in combined endpoints (hospitalization and deaths) in the intervention group than in the control group.

the open nutraceuticals journal

Randomized, Double Blind, Placebo Controlled Trial of Hydrosoluble Ubiquinol and Carnitine in Patients with Heart Failure: Longterm Follow up Results in the Tishcon Study